Previous 10 | Next 10 |
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing effica cy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 (GLOBE...
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (C...
Enrollment t riggers m ilestone p ayment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for...
2023-04-04 08:30:22 ET Clearmind Medicine ( CMND ) -51% . Nogin ( NOGN ) -45% . ZIM Integrated Shipping Services ( ZIM ) -24% . AMC Entertainment Holdings ( AMC ) -24% rises on filed settlement of stock conversion lawsuit. Chicken Soup f...
PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT ICEBERG Canada NewsWire VANCOUVER, BC , April 4, 2023 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) (" Palisades " or the " Company ") today announced that New Found Gold Corp. (" New Found "), a signifi...
2023-04-03 13:28:55 ET Gainers: Guardforce AI ( GFAI ) +126% . Nogin ( NOGN ) +110% . Harbor Custom Development ( HCDI ) +33% . Indonesia Energy Corporation ( INDO ) +30% . Pulse Biosciences ( PLSE ) +29% . Barnwell Industrie...
2023-04-03 10:02:08 ET Gainers: Heska ( HSKA ) +20% . Heron Therapeutics ( HRTX ) +19% . InterCure ( INCR ) +17% . Innate Pharma ( IPHA ) +15% . Apellis Pharmaceuticals ( APLS ) +14% . Losers: OncoSec Medical ( ONCS...
2023-04-03 09:13:10 ET Palisade Bio ( NASDAQ: PALI ) shares down more than 30% in Monday's premarket session after announcing to issue 2,272,723 shares of common stock in a registered direct offering and concurrent private placement, at $2.64, which is less than its curren...
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors...
2023-04-03 08:16:44 ET OncoSec Medical ( ONCS ) -62% clinical data of the KEYNOTE-695 trial assessing TAVO EP in combination with KEYTRUDA (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. Ascendis Pharma ( ASND ) -38% after FD...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...